Supplementary Figure S4 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Year: 2024
Type: supplementary-materials
Abstract: Genes differentially expressed as a function of BOR on day 8. (A) Linear discriminant analysis of Log2 fold change in expression levels of 780 genes in patients stratified based on BOR. PR: partial response; SD: stable disease; PD: progressive disease. (B) Genes that maximally discriminate between PR and PD patients enrolled in combination therapy arm. * p<0.05 by Mann-Whitney U-test.
Authors: Mark Yarchoan, John D. Powderly, Bruno R. Bastos, Thomas B. Karasic, Oxana V. Crysler, Pamela N. Munster, Meredith A. McKean, Leisha A. Emens, Yvonne M. Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C. Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W. Dubensky, Sam H. Whiting, Susanna V. Ulahannan
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4394914907